International Clinical Trial: A Study to Evaluate the Intracranial Arterial Recanalization With Multiple Doses of LT3001 Drug Product in AIS Participant

Geneva, Nov. 2 -- International Clinical Trials Registry received information related to the study (NCT07890298) titled 'A Study to Evaluate the Intracranial Arterial Recanalization With Multiple Doses of LT3001 Drug Product in AIS Participant' on Oct. 16.

Study Type: Interventional

Study Design: Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Basic Science. Masking: None (Open Label).

Primary Sponsor: Lumosa Therapeutics Co., Ltd.

Condition: Acute Ischemic Stroke

Intervention: Drug: LT3001 Drug Product

Recruitment Status: Recruiting

Phase: Phase 2

Date of First Enrollment: October 1, 2026

Target Sample Size: 10

Countries of Recruitment: Taiwan

To know more, visit https://clinicaltrials.gov...